One of the earliest widespread applications of precision medicine in cancer care is helping patients and physicians decide whether chemotherapy is needed, a new study finds.
A transcription factor known as Snail1 can act as a “molecular bypass” that diminishes the natural tumor suppressing action of a gene called p53 in breast cancer patients, a new study finds.
As part of the Cancer Moonshot, representatives from government, academic, pharmaceutical and diagnostic companies are launching a new partnership in pursuit of creating an open database for liquid biopsies to potentially accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit.
Julie C. Brabbs, MBA, was named Cancer Center chief administrative officer. She will also serve as associate director for administration for the center’s National Cancer Institute Cancer Center Support Grant.
The University of Michigan Comprehensive Cancer Center is one of 12 sites to join Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
The University of Michigan Comprehensive Cancer Center has appointed four new leaders to oversee the direction and operation of its research enterprise.
The technique could one day help screen potential cancer treatments based on an individual patient's tumor and help researchers better understand cancer stem cells.
Eric Fearon, M.D., Ph.D., has been named director of the University of Michigan Comprehensive Cancer Center.
A small device implanted under the skin can improve breast cancer survival by catching cancer cells, slowing the growth of tumors.
U.S. News & World Report rankings places the U-M Comprehensive Cancer Center ranks first in Michigan.